The Results Of Phase III Clinical Protective Efficacy Of Zhifei Recombinant Protein New Crown Vaccine Were Published, And It Still Has High Protective Efficacy Six Months After Vaccination

take 3 minutes to read
Home News Main article

< a ALT = "697" id = "sign" > < / a > recently, the New England Journal of Medicine published online the results of the international multicenter randomized, double-blind, placebo-controlled phase III clinical trial of the recombinant protein subunit newcrown vaccine zf2001 jointly developed by the Gaofu academician team of the Institute of Microbiology of the Chinese Academy of Sciences and Zhifei Biology (300122).

The results showed that zf2001 could effectively prevent COVID-19 of different severity and was safe and well tolerated.

In the long-term effectiveness analysis (as of December 15, 2021) after completing the whole course of vaccination for about 6 months, the protective efficacy of the vaccine against COVID-19 of different severity can still reach 75.7%, and the protective efficacy against severe and critical COVID-19 can reach 87.6%; The protective effect on death caused by COVID-19 was 86.5%.

The protection rate of delta mutant was still as high as 76.1%, while that of alpha mutant was 88.3%; It is suggested that the vaccine still has high protective effect half a year after the whole process of vaccination.

16163753996664t4wyy.png

6123805

Ningde Times Issued An Investor Research Announcement Late At Night, Once Falling More Than 10% In The Session, And The Negotiated Price Adjustment Has Been Basically Completed
« Prev 05-05
Soundcloud Announced The Acquisition Of Musiio And Is Committed To Building A New Generation Of Discovery Engine
Next » 05-05